Whoa - what an awful day
I'm trying to reflect on what happened.
My overall view has not changed from earlier today...
https://hotcopper.com.au/posts/46442556/singleWe've had 68m MSB share traded today, where are all this selling coming from?
Unfortunately, this was the "professional" sharts exit strategy - how & why can they be so consistent with their execution of buying shorts and selling shorts - I'll leave it up to you for your imagination. But,
@maurico would have a stronger view on this
we'll see evidence of this shortly via the reported net short positions.
I wouldn't be surprised if they closed maybe 50% of all their short positions, so maybe down to 3% net short positions on Mesoblast!
Now, if that's the worst that can happen, i.e. I won't be witnessing a short squeeze - I'll live with it, but I don't have to like it. These sharts have gotten off far too lightly
Now back onto ODAC.
If SHs are surprised by the reported information then they are kidding themselves.
Mesoblast is bringing a paradigm shift in medical treatment and will have to wear the scrutiny of being the leader in this field, as well as the rewards of course.
This is all staging:
FDA and ODAC need to do their DD
Everything that needs to be discussed must be presented, but I have faith in SI & Team to be ready with the answers. If you read the ODAC briefing notes, then you read Mesoblast notes, they come at it from different angles.
FDA probe & pose the necessary questions.
Mesoblast methodologically respond to these questions.
Of course it has been discussed previously, otherwise FDA would not have supported Mesoblast to this point.
So again, if the manufacturing of Ryoncil is good enough for a rolling review, priority review, Covid-19 ARDS EAP & trial; and MIS-C EAP then it is good enough as a manufacturing solution for this niche aGVHD market.
Can you imagine an independent organisation (NIH) agreeing to sponsor the Covid-19 ARDS if they had concerns about batch to batch consistency?
It is not just a single organisation that needs to have comfort with the product that they are trialing, but all the hospitals and medical staff involved too. Would they be happy to be involved/ associated with a sham organisation - remember no one wants to look like a dill; and these people, hospitals and NIH have their reputation on the line too.
So, apart from the SP being targeted today - nothing has changed with the ODAC review and Mesoblast heading for it's first FDA product approval.
You either have faith in Mesoblast to deliver or not.
HODL is not easy, but have the conviction to hold on!
After waiting so many years, I'm not going to let any recent tourists ("experts") deter me from my position!
Now over to MESO and let the climb back begin
(20min delay)